The numbers are in, and biotech startups recently closed out their best fundraising quarter in two years, signaling that the industry downturn may soon be a thing of the past.
Venture-backed biopharma companies raised $6.8 billion in the first three months of the year, according to early data compiled by HSBC. That’s the largest amount raised since the first half of 2022.
That’s big news for an industry that has been icy for the last three years, once the attention the Covid pandemic brought to drug companies began to fade. Layoffs became commonplace. Landlords in places like greater Boston suddenly found they had vacant labs for the first time in a decade.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect